Document Detail

Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate.
MedLine Citation:
PMID:  11377130     Owner:  NLM     Status:  MEDLINE    
Forty infants, 6 to 36 mo old, with iron-deficiency anemia (hemoglobin < 11 g/dL) were matched and assigned to two groups. One group received FeS0(4) and the other received ferrous bis-glycinate chelate at a dose of 5 mg of Fe daily per kilogram of body weight for 28 d. Both groups had significant hemoglobin increases (P < 0.001), but only the group treated with ferrous bis-glycinate chelate had significant increases (P < 0.005) in plasma ferritin. Apparent iron bioavailabilities were calculated at 26.7% for FeS0(4) and 90.9% for ferrous bis-glycinate chelate. Regression analysis indicated that absorption of both sources of iron were similarly regulated by the body according to changes in hemoglobin. We concluded that ferrous bis-glycinate chelate is the iron of choice for the treatment of infants with iron-deficiency anemia because of its high bioavailability and good regulation.
O Pineda; H D Ashmead
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Nutrition (Burbank, Los Angeles County, Calif.)     Volume:  17     ISSN:  0899-9007     ISO Abbreviation:  Nutrition     Publication Date:  2001 May 
Date Detail:
Created Date:  2001-05-29     Completed Date:  2002-01-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8802712     Medline TA:  Nutrition     Country:  United States    
Other Details:
Languages:  eng     Pagination:  381-4     Citation Subset:  IM    
Latin American Center for Nutrition and Metabolic Studies, Antigua, Guatemala.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Iron-Deficiency / drug therapy*
Biological Availability
Child, Preschool
Double-Blind Method
Ferritins / blood
Ferrous Compounds / pharmacokinetics,  therapeutic use*
Glycine / analogs & derivatives*,  pharmacokinetics,  therapeutic use*
Hemoglobins / metabolism
Intestinal Absorption
Iron / blood,  pharmacokinetics
Iron Chelating Agents / pharmacokinetics,  therapeutic use*
Regression Analysis
Treatment Outcome
Reg. No./Substance:
0/Ferrous Compounds; 0/Hemoglobins; 0/Iron Chelating Agents; 0/bis-glycino iron II; 56-40-6/Glycine; 7439-89-6/Iron; 7720-78-7/ferrous sulfate; 9007-73-2/Ferritins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Vitamin and mineral supplement use by healthy teenagers in Korea: motivating factors and dietary con...
Next Document:  Effects of conjugated linoleic acid on serum leptin concentration, body-fat accumulation, and beta-o...